

Patient: John A. Doe



Case No: P11-00157

DOB/Gender: xx/xx/xxxx (70 yrs) - Male

SSN: xxx-xx-xxxx

MRN/ID: 123456

4 Science Park, New Haven, CT 06511
Phone: 203-787-7888 Fax: 203-901-1289
www.precipiodx.com

Collected: xx/xx/xx

Received: xx/xx/xx

Reported: xx/xx/xx

Provider: Jane Smith, M.D.

Account: Hematology Oncology Associates

Phone: 555-555-1234 **Fax:** 555-555-4321

Alert Status: Routine

Report Status: Partial

Report Category: **Abnormal**

Clinical information: ICD-10: D64.9, D69.6. Anemia, unspecified. Thrombocytopenia, unspecified.
Received CBC, reported on 3/6/2011: WBC 12.4; RBC 4.86; HGB 14.7; HCT 45.1; MCV 92.9; MCH 30.2; MCHC 32.6; RDW 14.1; PLT 191; MPV 8.2; LYM 54.7%; MON 'NP'; NEU 'NP'; EOS 'NP'; BAS 'NP' (NP = not provided)

Specimens received: 2 Green-top tubes, 1 lavender-top tube

Pending studies: Morphology
FISH (MDS)
Summary final report - expected on 3/9/11. Your patient's next appointment is on 3/12/11.



Professional Services Provided By
Yale SCHOOL OF MEDICINE

DIAGNOSIS:

Peripheral blood: 4% of total cellularity is comprised of myeloblasts

COMMENT:

Increased myeloblasts in peripheral blood, as well as atypical CD56 expression on monocytes. These findings can be seen in myeloid neoplasms such as Myelodysplastic Syndromes. Bone marrow biopsy is recommended for further evaluation, if clinically indicated.

Electronically Signed By: S. David Hudnall, MD, FCAP

INTERPRETATION:


The differential shows 4% blasts that are positive for the following markers: CD34, CD117, CD13, HLA-DR, CD33 and CD71. The monocytes (25%) show an aberrant CD56 expression. The lymphocytes (28%) include 7% polyclonal B-cells, 76% mature T-cells with an elevated CD4/CD8 ratio (6.1), and 13% natural killer (NK) cells.

RESULT:

Analysis Time: 03/07/11, 14:47

Viability: 99% (Normal > 80%)


Specimen: PB, Lavender-top tube




Flow Differential

Flow Cytometry Differential


Lymphocytes:	28%
Monocytes:	25%
Granulocytes:	32%
Blasts:	5%
Non-Lysed RBC & Debris:	8%




Elevated CD4/CD8 Ratio



CD34+/CD117+ Blasts



Polyclonal B-Lymphocytes



CD13+ Blasts

Blasts Gated Population (CD45 and side scatter)

T/NK-cell	%	Myelo/Mono	%	Precursor	%	B-Cell	%
CD3	6	HLA-DR	59	CD34	77	CD19	1
CD8	1	CD13	96	CD117	70	Kappa	<1
CD4	3	CD11b	23	TdT	1	Lambda	<1
CD56	3	CD16	3	Myeloperoxidase	21	CD20	<1
CD2	4	CD64	1			CD38	55
CD5	3	CD15	12			CD10	5
CD7	9	CD71	74				
cCD3	2	CD14	3				
		CD61	3				
		CD33	80				
Other	%	Red Blood Cells	%				
CD45	100	CD235a	14				

Granulocytes Gated Population (CD45 and side scatter)

T/NK-cell	%	Myelo/Mono	%	Precursor	%	B-Cell	%
CD4	3	HLA-DR	1	CD34	<1	CD19	3
CD56	3	CD13	93	CD117	1	CD10	74
		CD11b	99				
		CD16	85				
		CD64	31				
		CD15	99				
		CD71	<1				
		CD14	77				
		CD61	2				
		CD33	68				
Other	%						
CD45	100						

Lymphocytes Gated Population (CD45 and side scatter)

T/NK-cell	%	B-Cell	%	Other	%
CD3	76	CD19	7	CD45	100
CD8	11	Kappa	5		
CD4	67	Lambda	2		
CD56	14	CD20	7		
CD2	85	CD38	6		
CD5	76	CD10	<1		
CD7	89				
TCR pan alpha_beta	75				
TCR pan gamma_delta	6				
CD57	9				

Intensity: B = bright D = dim M = moderate

Disclaimer: The adequacy of staining is verified by the appropriate positive & negative controls. The reagents used for these assays are analyte specific reagents (ASR). Their performance characteristics have been validated by Precipio Diagnostics, LLC, New Haven, CT. They have not been reviewed by the FDA. The FDA has deemed that such approval is unwarranted. These assays are for clinical use and should not be viewed as experimental or "research use only".